Hoffmann-la Roche

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…

This study tests whether a new daily medication, fenebrutinib, is better than an existing drug (teriflunomide) at reducing relapses and slowing disability in adults with relapsing multiple sclerosis. About 746 participants will be randomly assigned to one of the two treatments. T…

This study tests whether adding a new drug called inavolisib to standard therapy (palbociclib and fulvestrant) can help people with a specific type of advanced breast cancer (PIK3CA-mutant, HR-positive, HER2-negative) live longer without their cancer growing. The trial enrolls 32…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE can help people with untreated liver cancer live longer without their disease getting worse. About 342 participants will be randomly assigned to…

This study offers ongoing treatment with alectinib or crizotinib to 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche study. The main goal is to track side effects and safety while patients continue therapy. Participants …

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging, pain, and double vision. The drug aims to reduce eye bulging by at least 2 millimeters over 24 weeks. Participants receive either the drug o…

This study tests a drug called obinutuzumab against a standard treatment (MMF) in children and young adults with a kidney condition that causes frequent relapses. The goal is to see if obinutuzumab can keep the disease in remission longer and reduce the need for steroids. About 8…

This study tests a drug called atezolizumab in 60 people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not had chemotherapy before. The goal is to see if the drug helps them live longer and controls the cancer. This is …

This study tests whether adding the drug tiragolumab to standard treatment (atezolizumab plus chemotherapy) helps people with untreated extensive-stage small cell lung cancer live longer without their cancer growing. About 123 participants in China will receive either the new com…

This study tests whether a new drug called tobemstomig, given with standard chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that hasn't been treated before. About 182 adults with stage I…

This early-phase study tests an experimental drug (RO7567132) alone or with another drug (atezolizumab) in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors…

This study tests an experimental antibody called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic disease that causes progressive muscle weakness. The drug blocks a protein that limits muscle growth, with the goal of preserving or increasing mu…

This study tests a drug called crovalimab in 83 adults and teens with atypical hemolytic uremic syndrome (aHUS), a rare disease that causes blood clots and kidney damage. The goal is to see if crovalimab can stop the disease from damaging the body. Participants must be vaccinated…

This study compares a new oral medication, fenebrutinib, to an existing drug, teriflunomide, in adults with relapsing multiple sclerosis (MS). The goal is to see if fenebrutinib better reduces relapses and slows disability progression. About 751 participants will take one of the …

This study tests a new drug, crovalimab, in about 50 people with a rare blood disease called PNH. The goal is to see if the drug can control the destruction of red blood cells and reduce the need for blood transfusions. Participants receive crovalimab for at least 24 weeks, and t…

This study tests several different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers are selecting treatments based on specific biomarkers (genetic markers) in each patient's tumor. The main goal is to see how long the …

This study tests a gene therapy (delandistrogene moxeparvovec) in children under 4 with Duchenne muscular dystrophy. The goal is to see if it is safe and helps produce a key muscle protein. About 13 children will receive the treatment and be followed for over 5 years.

This study tests a new drug called giredestrant against standard hormone therapies for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 300 participants whose cancer had worsened after 1-2 prior treatments were randomly assigned to receive e…

This study tests a drug called faricimab given as an eye injection every 24 weeks (about twice a year) in people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if this longer dosing schedule can maintain or improve vision whil…

This study offers ongoing access to the cancer drug atezolizumab for up to 1,000 patients who previously benefited from it in a Roche-sponsored trial. Participants continue their treatment regimen to maintain disease control while researchers monitor side effects. The goal is to …

This early-stage study tests an experimental drug called RO7204239 in 30 adults with type 2 diabetes who are also overweight or obese. The main goal is to see if the drug improves how the body uses insulin, compared to a placebo. Researchers will also check changes in blood sugar…

This study tests whether a combination of two drugs (atezolizumab and bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 668 adults with liver cancer at high risk of recurrence will either recei…

This study tests an experimental daily pill, RO7269162, in people at risk for or in the early stages of Alzheimer's disease. The goal is to see if it safely reduces harmful brain plaques (amyloid) and affects other disease markers. About 256 participants will take the drug or a p…

This study tested whether the immunotherapy drug atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. About 1,280 people with stage IB to IIIA non-small cell lung cancer took part. Half received atezolizumab for about a year, while the other …

This study follows 1,000 Chinese adults with diffuse large B-cell lymphoma (DLBCL) to see how well polatuzumab controls the cancer in everyday clinical practice. Participants include those who are frail, those who are not, and those whose cancer has returned or not responded to p…

This study tests a medicine called crovalimab in 41 children with a rare disease called atypical hemolytic uremic syndrome (aHUS). The goal is to see if the drug can control the disease and improve kidney function. Participants must be at least 5 kg and have certain vaccinations …

This study tests whether a newer drug, entrectinib, works better than the current standard, crizotinib, in people with advanced ROS1-positive non-small cell lung cancer, including those whose cancer has spread to the brain. About 220 participants will take one of the two pills da…

This study tests a new once-daily medicine called RO7795081 to see if it helps control blood sugar in adults with type 2 diabetes. About 240 participants will take the drug, a placebo, or an active comparator (semaglutide) for 30 weeks. The main goal is to measure changes in HbA1…

This study tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS), including those with more advanced disease. About 1,000 participants receive either the drug or a placebo, and researchers measure changes …

This study tests a drug called giredestrant in 30 people with Grade 1 endometrial cancer. The goal is to see if the drug can shrink or control the cancer over 6 months without surgery. Participants take the drug daily and have regular biopsies to check progress.

This study tests whether the immunotherapy drug atezolizumab can delay or prevent bladder cancer from coming back after surgery. It includes 761 high-risk patients whose blood tests show signs of remaining cancer DNA. Participants receive either atezolizumab or a placebo to see i…

This study tests an experimental drug called RO7790121 in 21 adults with moderate to severe Crohn's disease who haven't responded well to standard treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and abdominal pain. Partici…

This study tests two new immunotherapy drugs, tobemstomig alone or with tiragolumab, against an existing drug (atezolizumab) in 204 people with advanced bladder cancer who cannot receive standard platinum chemotherapy. The goal is to see if these combinations are safer and more e…

This study tests a new drug, giredestrant, combined with palbociclib, against a standard treatment (letrozole plus palbociclib) for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive either the new combination or …

This study tests the safety and best dose of ocrelizumab in 23 children and teens aged 10 to 18 with relapsing-remitting multiple sclerosis. Over 2 years, researchers will monitor how the drug moves through the body and its effects on immune cells. The goal is to prepare for a la…

This study tests whether adding an experimental drug (RO7204239) to an existing weight-loss medication (tirzepatide) helps people with obesity or overweight lose more weight. About 285 adults without diabetes will take the combo or a placebo for 48 weeks, then stop tirzepatide an…

This study tests a new drug, glofitamab, added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and works better at controlling the cancer. About 46 adults with unt…

This study tests an experimental antibody drug called prasinezumab in people with early Parkinson's disease. The goal is to see if it can slow down worsening of symptoms over 52 weeks compared to a placebo. The trial involves 316 participants and includes a long-term extension to…

This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in adults with antiphospholipid syndrome (APS), an autoimmune condition that raises clot risk. The trial was withdrawn before enrolling any participants, so no results ar…

This study tests a new medicine called zifibancimig for people with wet age-related macular degeneration, a leading cause of vision loss. The drug is given as an eye injection or through a small implant in the eye. The goal is to see if it is safe and can help control the disease…

This study tests an experimental drug called obinutuzumab in 303 people with active lupus. The goal is to see if adding this drug to standard treatment can better control lupus activity and reduce flares. Participants receive either obinutuzumab or a placebo, and researchers meas…

This study tests whether taking alectinib pills for two years after lung cancer surgery works better than standard chemotherapy at preventing the cancer from returning. It includes 257 adults with a specific genetic type of lung cancer (ALK-positive) that was removed completely. …

This study looks at how a medicine called emicizumab affects joint health, physical activity, and overall well-being in people aged 13 to 69 with moderate or severe hemophilia A. Participants receive emicizumab as a regular shot to prevent bleeding. The goal is to see if it reduc…

This early-stage study tests a new medicine called RO7790121 in 50 adults with advanced liver scarring from MASH (a type of fatty liver disease). The main goal is to check safety and how the drug moves through the body. Participants must have severe fibrosis (stage F3 or F4) and …

This study tests a drug called satralizumab in 131 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging, pain, and double vision. The drug aims to reduce eye bulging by at least 2 millimeters over 24 weeks. Participants receive either the drug o…

This study tests whether a higher dose of the drug ocrelizumab can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS will receive either the standard dose or a higher dose every 24 weeks. The main goal is t…

This study tests whether adding an experimental drug (RO7204239) that helps muscles grow to an existing SMA treatment (risdiplam) can improve motor function more than risdiplam alone. About 259 people with SMA, aged 2 to 25 years, will take part. The trial first finds the best do…

This study tests whether adding a new drug (giredestrant) to standard therapy (Phesgo) can help people with a certain type of advanced breast cancer (HER2-positive and ER-positive) live longer without their cancer growing. About 922 participants will receive either the combinatio…

This study tests a new treatment called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy), a leading cause of vision loss. The treatment uses special cells grown from stem cells that are placed under the retina to replace damaged cells. Th…

This study tests a new once-daily drug, RO7795081, for helping people with obesity or overweight who also have weight-related health problems like high blood pressure or sleep apnea. About 340 adults will take either the drug or a placebo for 38 weeks to see how much weight they …

This study tested the drug ocrelizumab in 927 adults with progressive multiple sclerosis (MS) to see if it can slow down worsening of the disease. Participants received the drug for up to 4 years, and researchers measured how many had no signs of disability getting worse. The goa…

This study tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if this combination works better than the current standard treatmen…

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. A simple blood test identifies specific genetic changes in the tumor, allowing doctors to match each patient with a drug that may work better for their cancer. The goal …

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This study tests an experimental drug called entrectinib in children and teens with advanced solid tumors or brain cancers that have come back or not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors, especially in those with…

This study is testing several new drugs that are chosen based on the specific genetic markers found in a person's rare ovarian tumor. It includes 176 adults whose ovarian, fallopian tube, or peritoneal cancer has come back or not gone away after standard treatment. The goal is to…

This study tests a new medicine, crovalimab, in healthy volunteers and people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. The goal is to see if the drug is safe and can control the disease by blocking part of the immune syst…

This study tests an experimental drug called fenebrutinib in people with relapsing multiple sclerosis (RMS). The goal is to see if it can reduce new brain lesions seen on MRI scans compared to a placebo. About 109 participants will take either the drug or a placebo for 12 weeks, …

This study allows cancer patients who were already benefiting from atezolizumab in a previous Roche-sponsored trial to keep receiving the drug if they have no other local options. It includes 49 participants and focuses on safety and continued treatment access. The goal is to ens…

This study looks at how breast cancer is diagnosed and treated in Latin America. It will follow about 2,900 newly diagnosed patients to understand their cancer types, treatments, and outcomes. No new treatments are being tested—the goal is to gather information to improve future …

This study follows about 800 people with ALK-positive advanced non-small cell lung cancer who are taking alectinib as part of their routine care. Researchers are collecting data on how long the cancer stays under control, survival rates, and treatment patterns. The goal is to und…

This study is not testing a new treatment but rather collecting information from about 6,000 adults already receiving approved Roche eye medications for conditions like wet age-related macular degeneration and diabetic macular edema. The goal is to understand how well these drugs…

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer that cannot be removed by surgery. Researchers will collect information from medical records and over time to see what treatments doctors actually use, how long patients live, and wh…

This study follows over 2,700 cancer patients (with bladder, lung, or liver cancer) who are receiving the drug atezolizumab as part of their routine care. Researchers are tracking how long patients live and how well the drug controls their cancer, without giving any experimental …